Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tsumura & Co ( (JP:4540) ) just unveiled an update.
Tsumura & Co reported a decrease in its consolidated financial results for the first quarter ending June 30, 2025, with net sales slightly declining by 1.4% and significant drops in operating profit and ordinary profit by 27.0% and 56.2%, respectively. The company’s projections for the fiscal year ending March 31, 2026, indicate a modest increase in net sales by 3.8%, but a continued decline in profits, reflecting challenges in maintaining profitability amidst market conditions.
The most recent analyst rating on (JP:4540) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
More about Tsumura & Co
Tsumura & Co is a company listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry. It specializes in the production and distribution of traditional Japanese Kampo medicines, focusing on providing herbal remedies to the healthcare market.
Average Trading Volume: 663,290
Technical Sentiment Signal: Hold
Current Market Cap: Yen284.1B
See more data about 4540 stock on TipRanks’ Stock Analysis page.